Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib-Reference-Cited by-同舟云学术

Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib

Published:2011-03-01 Issue:10 Volume:17 Page:3304-3315
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Mileshkin Linda,Hicks Rodney J.,Hughes Brett G.M.,Mitchell Paul L.R.,Charu Veena,Gitlitz Barbara J.,Macfarlane David,Solomon Benjamin,Amler Lukas C.,Yu Wei,Pirzkall Andrea,Fine Bernard M.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lesion Analysis in PERCIST 1.0: Clinical Ease versus Research Requisite—Where Does the Balance Exist?;World Journal of Nuclear Medicine;2023-04-28

2. A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition inBRAFV600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study;Clinical Cancer Research;2023-01-13

3. New PET Tracers: Current Knowledge and Perspectives in Lung Cancer;Seminars in Nuclear Medicine;2022-11

4. The Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Predicting Treatment Response Before EGFR TKI Treatment in Patients with Advanced Lung Adenocarcinoma;Molecular Imaging and Radionuclide Therapy;2022-06-01

5. A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and 18F-FDG Metabolic Activity in Non-Small Cell Lung Cancer;Frontiers in Oncology;2022-04-20